B-cell prolymphocytic leukemia (B-PLL) is a rare, aggressive type of leukemia that progresses rapidly. People with B-PLL typically have a less favorable outlook. However, new targeted treatments ...

Recognition of specific antigen through the B-cell receptor (BCR) stimulates the activation of B cells, which ultimately results in the production of high-affinity antibodies and the provision of ...

The FDA has approved a new three-drug combination to treat certain types of an aggressive blood cancer called large B-cell lymphoma (LBCL).

Many foods are often advertised for their antioxidant properties. Antioxidants counteract what are known as reactive oxygen ...

An investigational induced pluripotent stem cell-derived CAR natural killer cell therapy was well tolerated both as monotherapy and in combination with rituximab among patients with B-cell ...

The pre-B-cell receptor (pre-BCR), which comprises two Igμ chains and two germline-encoded surrogate light chains (SLC) that are associated with the signalling subunits Igα and Igβ, is formed ...